Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Line K Vibholm

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Lancet Regional Health. Europe|November 7, 2022
High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trialKristoffer S Hansen, Trine H Mogensen, Jane Agergaard, et al.
Frontiers in Cellular and Infection Microbiology|July 22, 2022
CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist ImmunotherapyStine Sofie Frank Lende, Marie Høst Pahus, Ida Monrad, et al.
Open Forum Infectious Diseases|July 14, 2021
Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral EvolutionIda Monrad, Signe Risgaard Sahlertz, Stine Sofie Frank Nielsen, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|November 17, 2021
The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 InfectionMichelle Møhlenberg, Ida Monrad, Line K Vibholm, et al.
Iscience|September 4, 2023
Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1Lamin B Cham, Jesper D Gunst, Mariane H Schleimann, et al.
Ebiomedicine|June 7, 2021
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severityStine Sf Nielsen, Line K Vibholm, Ida Monrad, et al.
AIDS (London, England)|April 2, 2019
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individualsLine K Vibholm, Christina V Konrad, Mariane H Schleimann, et al.
Journal of Virology|February 1, 2019
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment InterruptionLine K Vibholm, Julio C C Lorenzi, Joy A Pai, et al.
Ebiomedicine|February 2, 2021
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responsesLine K Vibholm, Stine S F Nielsen, Marie H Pahus, et al.
Clinical and Experimental Immunology|April 10, 2026
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised PatientsIda M Johannsen, Line K Vibholm, Giacomo S Frattari, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Lancet Regional Health. Europe|November 7, 2022
High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trialKristoffer S Hansen, Trine H Mogensen, Jane Agergaard, et al.
Frontiers in Cellular and Infection Microbiology|July 22, 2022
CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist ImmunotherapyStine Sofie Frank Lende, Marie Høst Pahus, Ida Monrad, et al.
Open Forum Infectious Diseases|July 14, 2021
Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral EvolutionIda Monrad, Signe Risgaard Sahlertz, Stine Sofie Frank Nielsen, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|November 17, 2021
The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 InfectionMichelle Møhlenberg, Ida Monrad, Line K Vibholm, et al.
Iscience|September 4, 2023
Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1Lamin B Cham, Jesper D Gunst, Mariane H Schleimann, et al.
Ebiomedicine|June 7, 2021
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severityStine Sf Nielsen, Line K Vibholm, Ida Monrad, et al.
AIDS (London, England)|April 2, 2019
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individualsLine K Vibholm, Christina V Konrad, Mariane H Schleimann, et al.
Journal of Virology|February 1, 2019
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment InterruptionLine K Vibholm, Julio C C Lorenzi, Joy A Pai, et al.
Ebiomedicine|February 2, 2021
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responsesLine K Vibholm, Stine S F Nielsen, Marie H Pahus, et al.
Clinical and Experimental Immunology|April 10, 2026
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised PatientsIda M Johannsen, Line K Vibholm, Giacomo S Frattari, et al.
Pageof 2